Summary
Cannot evaluate alignment with FDA prescribing information because no AI-generated drug-label claims were provided to audit; the content appears to be a label-summary/verification narrative without an explicit set of claims attributable to an AI response for comparison.
Category Scores
Accurate Statements
Unsupported Statements
The excerpts provided match DUPIXENT prescribing information text with “Revised: April 2026” (consistent with the FDA-approved label content you included).
No specific FDA label text or versioning evidence was supplied in a way that can be independently verified against an authoritative label within this audit input.
Contradictions
Important Omissions
The exact AI-generated response (the statements to be evaluated) was not provided as a discrete text body; the audit input instead contains an analysis template and label excerpts, without a clear mapping of AI claims to label assertions.
Importance:
High
Safety Assessment
Potential Patient Risk:
Unknown
Because the claim-evaluation target (the AI-generated medical statements) is not present, safety impact of any inaccurate or omitted label content cannot be assessed.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Cannot Audit
Primary Issue
No explicit AI-generated drug-label claims were provided for comparison against the supplied FDA label excerpts.
Suggested Improvement
Provide the exact AI response text to be audited (all statements to evaluate), and specify which FDA label sections (e.g., 1.1/1.2/2.1/4/5.4/6.1/8.4) correspond to each statement.